Today, China’s National Food and Drug Administration (NMPA) drug approval certificate pending information shows that the KIT and PDGFRA mutant kinase inhibitor avapritinib (previously used Chinese name: apotinib) declared by CStone Pharmaceuticals is already available China was approved.
It is reported that the approved indication for avatinib this time is: for the treatment of unresectable or metastatic gastrointestinal stromal tumor (GIST) adult patients with PDGFRA exon 18 mutation (including PDGFRA D842V mutation).
Avatinib is a highly specific KIT and PDGFRA mutant kinase inhibitor developed by Blueprint Medicines.
CStone Pharmaceuticals obtained the exclusive development and commercialization authorization of the drug in Greater China in 2018.
According to reports, avatinib can directly bind to the active kinase that leads to mutations in KIT and PDGFRA signaling, thereby exerting a tumor suppressor effect.
It has shown extensive inhibitory effects in gastrointestinal stromal tumors with KIT and PDGFRA mutations, including the inhibitory effects of activation loop mutations that are resistant to existing therapies.